Virtual Incision Corp. raised $46 million in a series C funding round to support commercialization of its miniaturized in vivo robotic assistant (MIRA) for laparoscopic surgery. The first member of the company’s family of mini-robots in development targets colon surgery. Others in the pipeline will address hernia repair, gallbladder removal, sleeve gastrectomy, hysterectomy and other surgeries with specialized ranges of motion and tools.
While the FDA’s reaction to the results of the Nov. 30 advisory hearing for the COVID-19 therapy molnupiravir is difficult to predict, demand for rapid antigen tests may jump considerably when this or any such product is approved. That increased demand could crunch supplies of these tests due to the convergence of any such approvals, the upcoming holiday season, and the 2021-22 flu season, a convergence that could hamper efforts to roll out these new therapies.
PERTH, Australia – Medtech newcomer Artrya Ltd. listed on the Australian Securities Exchange (ASX) in an AU$40 million (US$28.6 million) initial public offering to commercialize its software that analyzes heart computed tomography (CT) scans via artificial intelligence (AI) to better diagnose coronary artery disease.
GE Healthcare Ltd. is expanding its cancer technology capabilities through new alliances with artificial intelligence (AI) companies and researchers. The company said it is teaming up with U.K.-based Optellum Ltd. to advance lung cancer diagnostics, as well as collaborating with the University of Cambridge to develop an AI application that integrates cancer patient data from multiple sources into a single interface.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arterys, Astrazeneca, Copado, Genetron, Happify, Icad, Igenomix, Vitrolife.
New hires and promotions in the med-tech industry, including: 23andme, Icecure Medical, Immunovia, Inflammatix, Informed DNA, Inspira Technologies, Oncohost.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acurable, AMF Medical, Corsano Health, Enlitic, Esaote, Immunexpress, Iterative Scopes, Sprintray.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Artio Medical, Dia Imaging, Nevro, Relievant Medsystems, Quit Genius.
The U.S. SEC released guidance Nov. 29 that could impact how drug and medical device companies shape, and report, their executive compensation packages when it comes to "spring-loaded awards.”
The FDA cleared Hyperfine Research Inc.’s advanced image reconstruction technology using deep learning for its portable magnetic resonance imaging device, Swoop. The bedside MRI unit’s artificial intelligence application received clearance in January and is used with deep learning to improve image quality and diagnostic value. Hyperfine and Liminal Sciences Inc., which share a founder in serial entrepreneur Jonathan Rothberg, are both combining with special purpose acquisition company Healthcor Catalio Acquisition Corp. to go public in a deal valued at $580 million. The companies reported on Nov. 29 that the Securities and Exchange Commission declared the registration statement on form S-4 for the combination to be effective and the SPAC’s shareholders will vote on the transaction on Dec. 21.
RSS
